Synthesis and in vitro evaluation of neurotoxicity and MAOA/B inhibitory effects of new pyrrolyl-based furan, substituted furan and indole azomethine derivates
DOI:
https://doi.org/10.2478/amb-2026-0042Keywords:
pyrrole hydrazones, neurotoxicity, MAOA/B inhibitionAbstract
Abstract. In this study the synthesis of three new N-pyrrolyl azomethine derivatives comprising furan, substituted furan and indole residues is presented. A classical Paal-Knorr cyclization was used for synthesis of the initial N-pyrrolyl hydrazine and the final azomethines were obtained in a micro synthesis scale, assuring about 69–76% yields, low harmful emissions and reagent economy. The compounds were elucidated by IR, 1H NMR and 13C NMR spectral analyses and the obtained results were consistent with the assigned structures. The purity of the substances was proven by TLC characteristics and corresponding melting points. In addition, the neurotoxicity and possible MAO-A and MAO-B inhibitory effects were elucidated in vitro. The obtained results indicated that the target molecules are with low neurotoxicity and no MAOA/B enzyme inhibiting effects.
References
Dnyandev GG, Sugandhi VV, Jha SK, et al. Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance. Ageing Res Rev, 2024, 99:102357. doi: 10.1016/j.arr.2024.102357.
Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci, 2006, 7(4):295-309. doi: 10.1038/nrn1883.
Hong R, Li X. Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches. Medchemcomm, 2018, 10(1):10‑25. doi: 10.1039/c8md00446c.
Park JH, Ju YH, Choi JW, et al. Newly developed reversible MAO‑B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease. Sci Adv, 2019, 5(3):eaav0316. doi: 10.1126/sciadv.aav0316.
Manzoor S, Hoda N. A comprehensive review of monoamine oxidase inhibitors as anti‑Alzheimer’s disease agents: A review. Eur J Med Chem, 2020, 206:112787. doi: 10.1016/j.ejmech.2020.112787.
Cai Z. Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer’s disease (Review). Mol Med Rep, 2014, 9(5):1533-1541. doi: 10.3892/mmr.2014.2040.
Burke WJ, Li SW, Schmitt CA, et al. Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer’s disease: mechanism of neuron death. Brain Res, 1999, 816(2):633-637. doi: 10.1016/s00068993(98)01211‑6.
Knittel J, Itani N, Schreckenberg R, et al. Monoamine Oxidase A contributes to serotonin‑ but not norepinephrine‑dependent damage of rat ventricular myocytes. Biomolecules, 2023, 13(6):1013. doi: 10.3390/biom13061013.
Sung JS, Kim S, Jung J, et al. Monoamine Oxidase-A (MAOA) inhibitors screened from the autodisplayed Fv‑antibody library. ACS Pharmacol Transl Sci, 2023, 7(1):150-160. doi: 10.1021/acsptsci.3c00204.
Baweja GS, Gupta S, Kumar B, et al. Recent updates on structural insights of MAO‑B inhibitors: a review on target-based approach. Mol Divers, 2024, 28(3):1823-1845. doi: 10.1007/s11030‑023‑10634‑6.
Davis SE, Cirincione AB, Jimenez-Torres AC, Zhu J. The Impact of neurotransmitters on the neurobiology of neurodegenerative diseases. Int J Mol Sci, 2023, 24(20):15340. doi: 10.3390/ijms242015340.
Dash UC, Bhol NK, Swain SK, et al. Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications. Acta Pharm Sin B, 2025, 15(1):15‑34. doi: 10.1016/j.apsb.2024.10.004.
Gallo A, Pillet LE, Verpillot R. New frontiers in Alzheimer’s disease diagnostic: Monoamines and their derivatives in biological fluids. Exp Gerontol, 2021, 152:111452. doi: 10.1016/j.exger.2021.111452.
Schedin-Weiss S, Inoue M, Hromadkova L, et al. Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels. Alzheimers Res Ther, 2017, 9(1):57. doi: 10.1186/s13195‑017‑0279‑1.
Jaisa-Aad M, Muñoz-Castro C, Healey MA, et al. Characterization of monoamine oxidase‑B (MAO‑B) as a biomarker of reactive astrogliosis in Alzheimer’s disease and related dementias. Acta Neuropathol, 2024, 147(1):66. doi: 10.1007/s00401‑024‑02712‑2.
Naffaa MM. Monoamine Oxidase B in astrocytic GABA synthesis: a central mechanism in neurodegeneration and neuroinflammation. J Cell Signal, 2025, 6(2):53-70.
Marucci G, Buccioni M, Dal Ben D, et al. Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease. Neuropharmacology, 2021, 190:108352. doi: 10.1016/j.neuropharm.2020.108352.
Rahman MS, Uddin MS, Rahman MA, et al. Exploring the role of monoamine oxidase activity in aging and Alzheimer’s Disease. Curr Pharm Des, 2021; 27(38):4017-4029. doi: 10.2174/1381612827666210612051713., Cheng Y, Lin F. NADPH and Alzheimer’s Disease and Parkinson’s Disease. In: Qin ZH (eds) Biology of Nicotinamide Coenzymes. 2025, Springer, Singapore. https://doi.
org/10.1007/978-981-97-9877-3_39.
Giménez-Xavier P, Gómez-Santos C, Castaño E, et al. The decrease of NAD(P)H has a prominent role in dopamine toxicity. Biochim Biophys Acta, 2006, 1762(5): 564-574. doi: 10.1016/j.bbadis.2006.02.003.
Kaludercic N, Arusei RJ, Di Lisa F. Recent advances on the role of monoamine oxidases in cardiac pathophysiology. Basic Res Cardiol, 2023, 118(1):41. doi: 10.1007/s00395-02301012‑2.
Iacovino LG, Reis J, Mai A, et al. Diphenylene iodonium is a noncovalent MAO inhibitor: a biochemical and structural analysis. Chem Med Chem, 2020, 15(15):1394-1397. doi: 10.1002/cmdc.202000264.
Taupin P, Zini S, Cesselin F, et al. Subcellular fractionation on Percoll gradient of mossy fiber synaptosomes: morphological and biochemical characterization in control and degranulated rat hippocampus. J Neurochem, 1994, 62(4):1586-1595. doi: 10.1046/j.1471‑4159.1994.62041586.x.
Mungarro-Menchaca X, Ferrera P, Morán J, Arias C. β-Amyloid peptide induces ultrastructural changes in synaptosomes and potentiates mitochondrial dysfunction in the presence of ryanodine. J Neurosci Res, 2002, 68(1):89-96. doi: 10.1002/jnr.10193.
Robyt JF, Ackerman RJ, Chittenden CG. Reaction of protein disulfide groups with Ellman’s reagent: A case study of the number of sulfhydryl and disulfide groups in Aspergillus oryzae α-amylase, papain, and lysozyme. Arch Biochem Biophys, 1971, 147(1):262-269. doi: 10.1016/0003-9861(71)90334-1.
Shirani M, Alizadeh S, Mahdavinia M, Dehghani MA. The ameliorative effect of quercetin on bisphenol A-induced toxicity in mitochondria isolated from rats. Environ Sci Poll Res, 2019, 26(8):7688-7696. doi: 10.1007/s11356-018-04119-5.
Ravindranath V, Anandatheerthavarada HK. Preparation of brain microsomes with cytochrome P450 activity using calcium aggregation method. Anal Biochem, 1990, 187(2):310313. doi: 10.1016/0003‑2697(90)90461‑h.
Mansuy D, Sassi A, Dansette PM, Plat M. A new potent inhibitor of lipid peroxidation in vitro and in vivo, the hepatoprotective drug anisyldithiolthione. Biochem Biophys Res Commun, 1986, 135(3):1015-1021. doi: 10.1016/0006-291x(86)91029-6.
Bautista-Aguilera OM, Esteban G, Bolea I, et al. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil‑indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer’s disease. Eur J Med Chem, 2014, 21(75):82-95. doi: 10.1016/j.ejmech.2013.12.028).
Georgieva M, Sharkov M, Mateev E, et al. Classical Paal-Knorr cyclization for synthesis of pyrrole‑based aryl hydrazones and in vitro/in vivo evaluation on pharmacological models of Parkinson’s disease. Molecules, 2025, 30: 3154. doi:10.3390/molecules30153154.
Molinspiration cheminformatics. [Internet], Accessed on September 2025. Available from: https://www.molinspiration.com/cgi/properties)
Abagyan R, Totrov M. High-throughput docking for lead generation. Curr Opinion Chem Biol, 200, 5(4):375-382 (https://molsoft.com/mprop/)
Gupta M, Lee HJ, Barden CJ, Weaver DF. The Blood-Brain Barrier (BBB) score. J Med Chem, 2019, 62(21):9824-9836. doi: 10.1021/acs.jmedchem.9b01220.
Scotti MT, Herrera-Acevedo C, de Menezes RPB, et al. Mol-PredictX: Online Biological Activity Predictions by Machine Learning Models. Mol Inform, 2022, 41(12):e2200133. doi: 10.1002/minf.202200133.
Gundersen V. Protein aggregation in Parkinson’s disease: protein aggregation in Parkinson’s Disease.” Acta Neurologica Scandinavica, 2010, 122:82-87. doi: 10.1111/j.16000404.2010.01382.x.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 M. Sharkov, M. Georgieva, M. Kondeva-Burdina (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
